inōtiv Corporate Presentation June 2023
Inotiv is Filling a Gap as a Middle Market CRO
Small Independent
Service Providers
inōtiv
analyze. answer. advance.
Annual Revenue
< $20 MM per entity
Service Orientation
One-off preclinical services
$548 MM¹
Large CROS
$ in billions
Comprehensive preclinical services, research models, and
some clinical services
Primarily clinical services;
some preclinical services
Client Base Profile
Emerging biopharma and specialty
support of large pharma
Competitive
Differentiation
Client service
Market
Fragmented
Characteristics
Emerging biopharma, small and medium pharma,
Universities, other CRO's, Governmental Entities
We provide "white glove" client service; agility to execute
comprehensive offerings from discovery through pre-
clinical with strong scientific acumen
Leader amongst middle-market CROs in North America
and Western Europe; no other provider with same breadth
of services and fewer than 10,000 people; agile and
responsive
Primarily large pharma
Breadth of services; cost plus;
room rate per hour
Consolidated at the top:
Charles River, Labcorp, ICON,
IQVIA, Medpace, PPD
8 |
1. FY 2022 revenue.
CORPORATE PRESENTATION
inōtiv
analyze, answer. advance.View entire presentation